See the paper attached: To view or add a comment, sign in An oral drug that treats symptomatic obstructive hypertrophic cardiomyopathy (oHCM) was recently approved by the US FDA
The supplement CDG is viewed as a potential clinical application for the regulation of estrogen metabolism and as a lipid-lowering agent (it helps maintain normal cholesterol levels)
How Can MinuteClinic Help Me with Primary Care
Quercetin-Induced Enhancement of Nasal Epithelial Cells Ability to Produce Clara Cell 10-kD Protein In Vitro and In Vivo
Induction of Glucose6Phosphate Dehydrogenase by Lipopolysaccharide Contributes to Preventing Nitric OxideMediated Glutathione Depletion in Cultured Rat Astrocytes. Journal of Neurochemistry 72: 17501758
Documented mechanisms of action Preclinical studies (mostly Russian, to be reproduced in international protocols) report several mechanistic targets: BDNF increase (Brain-Derived Neurotrophic Factor) in the hippocampus and frontal cortex, measured by ELISA and Western blot 24-72 h post-administration Monoaminergic system modulation : cortical dopamine increase, serotonergic modulation Activation of the melanocortin pathway via MC4R receptors (residue shared with ACTH) Anti-oxidant and anti-apoptotic effect in cerebral ischaemia models (MCAO, middle cerebral artery occlusion) Experimental paradigms The most reported rodent models are the Morris water maze (spatial memory), novel object recognition (recognition memory), passive avoidance (aversive learning)
